These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38306242)

  • 21. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
    Bröske AE; Korfi K; Belousov A; Wilson S; Ooi CH; Bolen CR; Canamero M; Alcaide EG; James I; Piccione EC; Carlile DJ; Dimier N; Umaña P; Bacac M; Weisser M; Dickinson M
    Blood Adv; 2022 Feb; 6(3):1025-1037. PubMed ID: 34941996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
    Budde LE; Assouline S; Sehn LH; Schuster SJ; Yoon SS; Yoon DH; Matasar MJ; Bosch F; Kim WS; Nastoupil LJ; Flinn IW; Shadman M; Diefenbach C; O'Hear C; Huang H; Kwan A; Li CC; Piccione EC; Wei MC; Yin S; Bartlett NL
    J Clin Oncol; 2022 Feb; 40(5):481-491. PubMed ID: 34914545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.
    Dufner V; Sayehli CM; Chatterjee M; Hummel HD; Gelbrich G; Bargou RC; Goebeler ME
    Blood Adv; 2019 Aug; 3(16):2491-2498. PubMed ID: 31451445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA
    Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting.
    Wang C; Liu Y
    J Hematol Oncol; 2023 Mar; 16(1):20. PubMed ID: 36895020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
    Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
    Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.
    Huang H; Zhu J; Yao M; Kim TM; Yoon DH; Cho SG; Eom HS; Lim ST; Yeh SP; Song Y; Kwong YL; Kim JS; Jin J; Shi Y; Kim H; Qing M; Zhou T; Gao G; Dong Z; Qi M; Kim WS
    J Hematol Oncol; 2021 Feb; 14(1):25. PubMed ID: 33588922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.
    Yu W; Huang L; Mei H; Li Y; Niu T; Zou D; Liu Y; Zhang H; Liu P; Wu J; Wang Z; Li H; Cai Q; Mi JQ
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38802271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
    Rentsch V; Seipel K; Banz Y; Wiedemann G; Porret N; Bacher U; Pabst T
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.